研究单位：[1]Chinese Academy of Medical Sciences,Fuwai Hospital[2]Yan'an Hospital affiliated to kunming medical university,Yunnan Cardiovascular Hospital Kunming,Yunnan,China,650051[3]The Second Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China,650101[4]The First Hospital of Kunming Kunming,Yunnan,China[5]First Affiliated Hospital of Xinjiang Medical University Urumqi,Xinjiang,China,830054[6]Pingjin Hospital,Logistics University of PAPF Tianjin,Tianjin,China,300162[7]College of Medicine,National Taiwan University Taibei,Taiwan,China[8]West China Hospital,Sichuan University Chengdu,Sichuan,China,610041[9]First Affiliated Hospital,Xian Jiaotong University Xi'an,Shanxi,China,710061[10]Shanxi Academy of Medical Sciences,Shanxi Dayi Hospital Taiyuan,Shanxi,China,030032
研究目的：
The Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) is a 2-arm, multi-center, prospective, randomized, open-labeled, blinded-endpoint trial. The purpose of this trial is to test whether a treatment program aimed at reducing systolic blood pressure (SBP) to a lower goal (<130 mmHg, intensive treatment) than currently recommended (<150 mmHg, standard treatment) will reduce CVD risk among persons between 60-80 years of old. Furthermore, this trial will also examine the effect of blood pressure APP management strategy via WeChat network on medication compliance, blood pressure control and CVD benefits.
